The short answer: cure is possible, but depends on when it's found
Lung cancer can be cured, but the chance depends heavily on what type of cancer it is, how far it has spread, and how soon it is caught. Cancers found early—before they have spread to other parts of the body—have much higher cure rates than those found late. A person with early-stage lung cancer may have a 50 to 90 percent chance of surviving five years or more after treatment, depending on the exact type. Advanced cancers that have spread widely have lower cure rates, though treatment can still extend life and control symptoms.
The word "cure" in cancer care means the cancer does not come back after treatment. Doctors cannot always promise a cure, but they can often control the disease for months or years, and sometimes for the rest of a person's life.
Key Takeaways
- Early-stage lung cancer has much higher cure rates than advanced cancer, which is why screening can make a real difference for people at high risk.
- The two main types of lung cancer—non-small cell and small cell—respond differently to treatment, and cure rates vary between them.
- Surgery, chemotherapy, radiation, targeted drugs, and immunotherapy are the main treatments, and many people receive a combination of them.
- Even when cure is not possible, modern treatments can slow the cancer's growth and give people more time and better quality of life.
How stage affects the chance of cure
Stage describes how far the cancer has spread. Doctors use stages 1 through 4, with stage 1 being the smallest and most localized, and stage 4 meaning the cancer has spread to distant parts of the body like the brain, bones, or liver.
Stage 1 and 2 lung cancers are often curable with surgery alone, especially if the tumor is small and has not reached the lymph nodes. Five-year survival rates for stage 1 non-small cell lung cancer (the most common type) range from 60 to 90 percent depending on the exact size and location. Stage 3 cancers are more difficult but still treatable with a combination of chemotherapy and radiation, or sometimes surgery followed by chemotherapy. Stage 4 cancers have spread too far for surgery to remove them all, so treatment focuses on slowing growth and managing symptoms rather than aiming for cure.
Non-small cell lung cancer versus small cell lung cancer
Non-small cell lung cancer (NSCLC) makes up about 85 percent of all lung cancers. It grows more slowly than small cell cancer and is more likely to be caught at an earlier stage. Early-stage NSCLC has the best cure rates—surgery can remove the tumor entirely in many cases.
Small cell lung cancer (SCLC) is less common but grows faster and spreads earlier. It is rarely caught at stage 1 or 2 because it has usually spread by the time symptoms appear. Even so, SCLC responds well to chemotherapy and radiation, and some people achieve long-term remission (a period where the cancer is not detectable). However, cure rates are lower than for NSCLC at the same stage.
Surgery, chemotherapy, and radiation as cure-focused treatments
Surgery is the most direct path to cure when the cancer is localized. A surgeon removes the tumor and nearby lymph nodes to make sure all cancer cells are gone. For stage 1 and early stage 2 cancers, surgery alone can cure the disease in many people. The surgery may remove just the tumor and a margin of healthy tissue, or it may remove an entire lobe of the lung (called a lobectomy).
Chemotherapy uses drugs to kill cancer cells throughout the body. It is often given before surgery (to shrink the tumor) or after surgery (to destroy any cells that may have been left behind). For stage 3 NSCLC, chemotherapy combined with radiation therapy is a standard approach aimed at cure. The combination works better than either treatment alone.
Radiation therapy uses high-energy beams to kill cancer cells. It can be used alone for people who cannot have surgery, or combined with chemotherapy. For stage 3 disease, concurrent chemoradiation (giving both at the same time) offers the best chance of cure, though it is more intense than giving them one after the other.
Newer treatments: targeted drugs and immunotherapy
In the past 10 to 15 years, doctors have developed drugs that target specific mutations in lung cancer cells. If a tumor has a mutation in the EGFR gene, ALK gene, or ROS1 gene, targeted drugs can be far more effective than chemotherapy. Some people with advanced lung cancer and these mutations have lived for many years on targeted therapy, though whether this counts as a "cure" is still being studied.
Immunotherapy drugs help the body's own immune system recognize and attack cancer cells. Drugs like pembrolizumab, nivolumab, and atezolizumab have improved survival for many people with advanced lung cancer. Some people have had their cancer shrink dramatically and stay controlled for years. Immunotherapy is now used for early-stage cancers too, given after surgery or chemotherapy to lower the risk that the cancer will return.
What happens after treatment ends
After treatment, people have follow-up visits with their oncologist (cancer doctor) to watch for signs that the cancer has returned. These visits usually happen every few months at first, then less often over time. Imaging scans like CT scans may be done to check for recurrence.
If the cancer does not return within five years, doctors often consider the person cured, though some cancers can return even after many years. People who have been treated for lung cancer have a higher risk of developing a second lung cancer later, so doctors may recommend screening with low-dose CT scans to catch any new cancer early.
Living with advanced lung cancer when cure is not the goal
When lung cancer has spread widely and cure is not realistic, treatment shifts to extending life and maintaining quality of life. Modern drugs can slow the cancer's growth for months or years. Some people live for several years with stage 4 lung cancer, especially if they have a mutation that responds to targeted therapy or if immunotherapy works well for them.
Palliative care—treatment focused on comfort rather than cure—becomes more important. This includes managing pain, shortness of breath, and other symptoms, as well as addressing emotional and practical concerns. Palliative care can be given alongside cancer treatment, not just at the end of life.
Frequently Asked Questions
What is the five-year survival rate for lung cancer?
The five-year survival rate varies widely by stage and type. For all stages combined, it is about 20 percent. But for stage 1 NSCLC, it can be 60 to 90 percent. For stage 4, it is much lower, around 5 to 10 percent. These are averages—individual outcomes depend on many factors including age, overall health, and how well the cancer responds to treatment.
Can lung cancer come back after five years?
Most recurrences happen within the first two to three years, but lung cancer can return even after five years or longer. This is why follow-up care continues for years after treatment. If cancer does return, it can sometimes be treated again, though the options depend on where it comes back and what treatments were used before.
Is there a difference in cure rates between smokers and non-smokers?
Cure rates are based on the cancer itself—stage, type, and mutations—not on smoking history. However, people who continue to smoke after a lung cancer diagnosis may have worse outcomes because smoking can interfere with healing and increase the risk of a second cancer.
Can immunotherapy cure lung cancer?
Immunotherapy has dramatically improved survival for many people with advanced lung cancer, and some have had their cancer disappear completely. Whether this counts as a "cure" is still being studied, since some people's cancers have returned years later. Immunotherapy is now used earlier in treatment to try to prevent recurrence.
What should I do if I have been diagnosed with lung cancer?
Meet with an oncologist who specializes in lung cancer to understand your specific diagnosis—the type, stage, and any genetic mutations. Ask about all treatment options and what the realistic goals are for your situation. Getting a second opinion from another oncologist is common and often recommended, especially for advanced cancer.